BioSpace News Archive

Nemaura Medical, Inc. announced that it now includes insulin on the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced that it will host a conference call and webcast to provide a business and clinical update on Tuesday, March 21, 2023 at 4:30 p.m. EDT.

Jaguar Health, Inc. announced that the Company, in advance of International Day of Forests, which takes place March 21, 2023, has achieved an important milestone related to the health of forest ecosystems, people, and communities in the Peruvian Rainforest.

BioLineRx Ltd. announced today that it will release its audited financial results for the year ended December 31, 2022 on Wednesday, March 22, 2023, before the U.S. market closes.

Clario today announced Rod MacKenzie CMG, PhD. as their new Chairman of the Board of Directors.

Compugen Ltd. today announced that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) annual meeting on April 14-19, 2023, in Orlando, Florida.

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today positive preclinical results from its lead program IG-002 addressing all forms of ABCA4-related retinopathies.

Stoke Therapeutics, Inc. today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022.

Prolira BV announced today it has received 510(k) clearance from the Food and Drug Administration (FDA) for the DeltaScan® Brain State Monitor to aid in the diagnosis of acute encephalopathy in hospitalized patients over 60 years of age.